Literature DB >> 25454318

Sensitive measures of executive dysfunction in non-demented Parkinson's disease.

Nicholas T Bott1, Erica T Johnson2, Norbert Schuff3, Nicholas Galifianakis4, Trishna Subas2, Jessica Pollock3, Peter Pressman2, Joel H Kramer2, Katherine L Possin2.   

Abstract

BACKGROUND: We examined the sensitivity of different executive function measures for detecting deficits in Parkinson's disease patients without dementia.
METHODS: Twenty-one non-demented PD subjects and 21 neurologically healthy controls were administered widely used clinical executive functioning measures as well as the NIH EXAMINER battery, which produces Cognitive Control, Working Memory, and Verbal Fluency scores, along with an overall Executive Composite score, using psychometrically matched scales.
RESULTS: No significant differences between groups were observed on widely used clinical measures. The PD patients scored lower than controls on the EXAMINER Executive Composite, Cognitive Control, and Working Memory Scores.
CONCLUSIONS: The NIH EXAMINER Executive Composite and Cognitive Control Scores are sensitive measures of executive dysfunction in non-demented PD, and may be more sensitive than several widely used measures. Results highlight the importance of careful test selection when evaluating for mild cognitive impairment in PD.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cognitive control; Executive function; Mild cognitive impairment; Parkinson's disease; Working memory

Mesh:

Year:  2014        PMID: 25454318      PMCID: PMC4314390          DOI: 10.1016/j.parkreldis.2014.10.007

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  16 in total

1.  Benefits of rivastigmine on attention in dementia associated with Parkinson disease.

Authors:  K A Wesnes; I McKeith; C Edgar; M Emre; R Lane
Journal:  Neurology       Date:  2005-11-22       Impact factor: 9.910

2.  Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia.

Authors:  Carmen Cristea Janvin; Jan Petter Larsen; Dag Aarsland; Kenneth Hugdahl
Journal:  Mov Disord       Date:  2006-09       Impact factor: 10.338

Review 3.  Executive dysfunction in Parkinson's disease: a review.

Authors:  Georg Dirnberger; Marjan Jahanshahi
Journal:  J Neuropsychol       Date:  2013-09       Impact factor: 2.864

4.  Verbal fluency in Parkinson's disease patients on/off dopamine medication.

Authors:  Elena Herrera; Fernando Cuetos; Renée Ribacoba
Journal:  Neuropsychologia       Date:  2012-09-18       Impact factor: 3.139

5.  Cognitive change in newly-diagnosed patients with Parkinson's disease: a 5-year follow-up study.

Authors:  Mark Broeders; Daan C Velseboer; Rob de Bie; Johannes D Speelman; Dino Muslimovic; Bart Post; Rob de Haan; Ben Schmand
Journal:  J Int Neuropsychol Soc       Date:  2013-04-02       Impact factor: 2.892

6.  The economic impact of cognitive impairment in Parkinson's disease.

Authors:  Corinna Vossius; Jan P Larsen; Carmen Janvin; Dag Aarsland
Journal:  Mov Disord       Date:  2011-04-29       Impact factor: 10.338

7.  Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis.

Authors:  D Aarsland; K Bronnick; C Williams-Gray; D Weintraub; K Marder; J Kulisevsky; D Burn; P Barone; J Pagonabarraga; L Allcock; G Santangelo; T Foltynie; C Janvin; J P Larsen; R A Barker; M Emre
Journal:  Neurology       Date:  2010-09-21       Impact factor: 9.910

8.  Psychometrically matched measures of global cognition, memory, and executive function for assessment of cognitive decline in older persons.

Authors:  Dan Mungas; Bruce R Reed; Joel H Kramer
Journal:  Neuropsychology       Date:  2003-07       Impact factor: 3.295

9.  Rivastigmine is associated with restoration of left frontal brain activity in Parkinson's disease.

Authors:  Katherine L Possin; Gail A Kang; Christine Guo; Eric M Fine; Andrew J Trujillo; Caroline A Racine; Reva Wilheim; Erica T Johnson; Jennifer L Witt; William W Seeley; Bruce L Miller; Joel H Kramer
Journal:  Mov Disord       Date:  2013-07-11       Impact factor: 10.338

10.  Executive functions in premanifest Huntington's disease.

Authors:  S Christine You; Michael D Geschwind; Sharon J Sha; Alexandra Apple; Gabriella Satris; Kristie A Wood; Erica T Johnson; Jonathan Gooblar; Jeanne S Feuerstein; Steven Finkbeiner; Gail A Kang; Bruce L Miller; Christopher P Hess; Joel H Kramer; Katherine L Possin
Journal:  Mov Disord       Date:  2013-12-27       Impact factor: 10.338

View more
  4 in total

Review 1.  Lewy body dementias.

Authors:  Zuzana Walker; Katherine L Possin; Bradley F Boeve; Dag Aarsland
Journal:  Lancet       Date:  2015-10-24       Impact factor: 79.321

Review 2.  MRI biomarkers of motor and non-motor symptoms in Parkinson's disease.

Authors:  Sephira G Ryman; Kathleen L Poston
Journal:  Parkinsonism Relat Disord       Date:  2019-10-10       Impact factor: 4.891

3.  Executive Functioning with the NIH EXAMINER and Inference Making in Struggling Readers.

Authors:  Kelly K Halverson; Jaye L Derrick; Luis D Medina; Paul T Cirino
Journal:  Dev Neuropsychol       Date:  2021-04-02       Impact factor: 2.253

4.  Is the Random Forest Algorithm Suitable for Predicting Parkinson's Disease with Mild Cognitive Impairment out of Parkinson's Disease with Normal Cognition?

Authors:  Haewon Byeon
Journal:  Int J Environ Res Public Health       Date:  2020-04-10       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.